Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
Biocon has secured a 10-year supply contract for Pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis. This agreement, part of Brazil's Productive Development Partnership (PDP) program, grants the consortium exclusive access to approximately 70% of Brazil's public healthcare market for Pertuzumab. Biocon is expected to receive milestone payments and a share of revenues over the contract's duration, with plans for phased localization in Brazil.
Biocon Limited approved and remitted a final dividend of ₹0.50 per equity share for the fiscal year 2025-26. The dividend was approved at the 48th Annual General Meeting held on August 6, 2026, and was electronically remitted to shareholders based on the record date of July 3, 2026, after applicable tax deductions.
As of September 18, 2026, Biocon's daily trend indicators suggest a bearish sentiment, with the Supertrend indicator at 404.62 and a 'bearish' direction. The 20-day Exponential Moving Average (EMA) is at 396.47, and the 50-day EMA is at 407.08, both above the current closing price of ₹385.0. However, the monthly trend shows a 'bullish' Supertrend at 276.45, indicating a different sentiment over a longer timeframe.
As of September 18, 2026, key technical levels for Biocon shares include immediate support near ₹384.5 (0.13% distance) and resistance around ₹388.31 (0.86% distance). Other identified resistance levels are at ₹389.0 and ₹396.0, while further support levels are noted at ₹377.5 and ₹373.0.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹4,336 crore | PEAK₹4,516.60 crore | ₹4,173 crore | ₹4,295.50 crore | ₹3,941.90 crore |
| Expenses | PEAK₹4,249.40 crore | ₹4,241.20 crore | ₹4,064.70 crore | ₹4,205.30 crore | ₹3,924.70 crore |
| Profit Before Exceptional Items And Tax | ₹141.10 crore | PEAK₹327.90 crore | ₹225.60 crore | ₹183.20 crore | ₹96.90 crore |
| Profit Before Tax | ₹127.60 crore | PEAK₹247.50 crore | -₹67.80 crore | ₹171.30 crore | ₹96.90 crore |
| Profit Loss For Period | ₹136.80 crore | PEAK₹198.60 crore | -₹51.80 crore | ₹132.80 crore | ₹89.20 crore |
| Tax Expense | -₹9.20 crore | PEAK₹48.90 crore | -₹16 crore | ₹38.50 crore | ₹7.70 crore |
Finance costs were ₹213.2 crore, down 8% from the prior quarter and 23% lower than the year-ago quarter. This follows a pattern of declining finance costs over the past several quarters. Inter-segment revenue fell sharply to ₹15.3 crore from ₹122.2 crore in the prior quarter, an 87% drop, and was also significantly below the ₹86.9 crore recorded in the same quarter last year.
Exchange disclosures and regulatory announcements for Biocon.
Biocon Limited approved a final dividend of ₹0.50 per equity share for the fiscal year 2025-26 at its 48th Annual General Meeting held on August 06, 2026. The company remitted these dividends electronically to shareholders based on the record date of July 03, 2026, with tax deductions applied as per applicable rates. This communication was issued on September 09, 2026, to inform shareholders who had not registered their email addresses and to direct them to verify credits via the Registrar & Share Transfer Agent, KFin Technologies Limited.
Biocon signed a partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, securing a 10-year supply contract under Brazil's Productive Development Partnership (PDP) program. The consortium received 100% allocation under the PDP, granting exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's Pertuzumab demand. Biocon will receive milestone payments and a share of revenues over the 10-year period, with phased localization in Brazil planned.
Biocon Limited scheduled an investor roadshow for September 11, 2026, in Mumbai, featuring one-on-one or group in-person interactions with analysts and institutional investors. The meeting was announced pursuant to Regulation 30(6) of the SEBI Listing Regulations by Company Secretary Rajesh U. Shanoy on September 8, 2026. The company explicitly stated that no unpublished price-sensitive information (UPSI) would be disclosed during the event.
Biocon Limited management will participate in the Nomura Asian Credit Corporate Day 2026 on September 4, 2026, as a virtual group interaction, as intimated to stock exchanges on August 31, 2026.
Biocon Limited approved a final dividend of ₹0.50 per equity share for the financial year 2025-26 at its 48th Annual General Meeting held on August 6, 2026. The company remitted these dividends electronically to shareholders as of the record date of July 3, 2026, with tax deducted at source according to applicable rates. This communication regarding the remittance was issued by Company Secretary Rajesh U. Shanoy on August 28, 2026.
On August 25, 2026, Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon Limited, received marketing approval from Japan's Ministry of Health, Labour and Welfare for its pegfilgrastim biosimilar. The product, a biosimilar to Neulasta®, will be promoted, sold, and distributed exclusively in Japan by Sandoz K.K., with Global Regulatory Partners Japan serving as the Marketing Authorization Holder.
Biocon Limited has informed the Exchange regarding 'Company Statement'. |SUBJECT: Updates
Biocon Limited reported Q1 FY27 results on August 6, 2026, with group operating revenue growing 10% year-on-year to INR4,351 crores and reported net profit before exceptionals rising 245% to INR145 crores. The biopharmaceutical segment drove growth with a 17% revenue increase to INR3,615 crores, while the services business (Syngene) saw revenues decline 16% to INR736 crores due to lower offtake from a key client. Management highlighted strong performance in biosimilars, including new launches of aflibercept and denosumab, and noted that interest costs decreased 23% year-on-year to INR213 crores as part of balance sheet strengthening efforts.
Recent market and company developments associated with Biocon.
Dr M Srinivas, Member (Health), NITI Aayog, emphasised the importance of academia-Industry partnership while addressing the 8th CII Pharma and Lifesciences Summit, themed Future of Pharma: Patient-Centric, Equity-Driven, and Innovation-Led, held on Friday in New Delhi in partnership with the Department of Pharmaceuticals.
The rise of technology is paving the way for younger Indians to step into leadership roles much earlier. Kiran Mazumdar-Shaw predicts that the notion of age-based distinctions might soon vanish. Driven by innovation, these young leaders are daring to take risks and develop groundbreaking business strategies. This fresh wave of leadership promises to significantly influence India's economic landscape, forging a path towards global ambitions fueled by technology.
India's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial first-in-human studies abroad. Other nations like the US and Australia offer faster approval processes for trials. China now leads in novel medicine development due to its streamlined regulatory environment. Reforming India's system can unlock its potential in novel drug innovation.
Biocon block deals,Biocon stock price,ICICI Prudential Mutual Fund,Activ Pine LLP
As of June 30, the total shareholding of Active Pine was 1.08% in Biocon, as per data available on the stock exchanges. With the entire equity having changed hands, Active Pine would have completely exited the stock.
Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Biocon, TCS, Bank of Baroda, NLC India, Innovision, GE Shipping, Moschip, Raymond, Berger Paints, Tata Consultancy Services, Enviro Infra Engineers, Moschip Technologies, Great Eastern Shipping Company, Laxmi Organic Industries, Fermenta Biotech
Indian equity markets hit a seven-week low on Tuesday, primarily due to escalating crude oil prices and geopolitical instability that swayed investor morale. Notably, Bank of Baroda announced plans to divest its interest in the NSE, while TCS secured a major contract. Other companies such as Sanofi India and Piramal Finance also shared pivotal developments, highlighting a mixed bag of corporate activity.
Shares of Biocon Ltd ended at ₹392.55, down by ₹0.95, or 0.24%, on the BSE.
Comprehensive Section Breakdown for Biocon
Strategic Vision: Global biopharmaceutical company focused on affordable innovation.
• Fully integrated drug value chain operations
• Focus on affordable innovation for unmet medical needs
• Strengths in manufacturing operations, research and development capabilities, and commitment to quality and compliance in Generics
• Extensive pipeline of novel biologics in oncology and immunology
Biocon Ltd.’s results for the quarter ended June 30, 2026 (FY2026-27 Q1) showed revenue falling from the prior quarter while total expenses remained nearly flat, narrowing the gap between income and costs. Compared with the same quarter a year earlier, both revenue and profit were higher. A tax credit and falling finance costs helped cushion the bottom line, though a sharp drop in inter-segment revenue and a divergence between net profit and earnings per share marked notable shifts in the quarter’s financial results.
Revenue from operations was ₹4,336 crore, down 4% from ₹4,516.6 crore in the March quarter, but up 10% from ₹3,941.9 crore in the same quarter last year. The sequential decline followed a March quarter that had been the highest revenue in the past five quarters. Total expenses were ₹4,249.4 crore, essentially unchanged from ₹4,241.2 crore in the prior quarter (up 0.2%), and 8.3% higher than the year-ago quarter. The combination of lower revenue and stable expenses narrowed the gap between revenue and expenses to ₹86.6 crore from ₹275.4 crore in the prior quarter.
Profit before exceptional items and tax fell to ₹141.1 crore from ₹327.9 crore in the prior quarter, a decline of 57%. The year-over-year comparison remained positive at ₹141.1 crore versus ₹96.9 crore, an increase of 46%. After accounting for exceptional items (a net charge of ₹13.5 crore), profit before tax was ₹127.6 crore, down 48% sequentially but up 32% from a year ago. Net profit for the period was ₹136.8 crore, down 31% from ₹198.6 crore in the prior quarter, but up 53% from ₹89.2 crore in the year-ago quarter. The sequential decline in net profit was less severe than the drop in pre-exceptional profit because the tax line turned into a ₹9.2 crore credit in the current quarter, compared to a ₹48.9 crore expense in the prior quarter, providing a partial offset.
Other comprehensive income was ₹788.8 crore, down 19% from ₹974.3 crore in the prior quarter. This item has shown significant volatility in recent periods, ranging from a loss of ₹205.5 crore in the first quarter of last year to gains exceeding ₹970 crore in subsequent quarters. Basic earnings per share from continuing operations was ₹0.87, up from ₹0.79 in the prior quarter and ₹0.26 a year ago. This sequential increase in per-share earnings occurred despite a decline in total net profit for the period, indicating a divergence between the two measures.
Biocon’s first quarter was characterized by a sequential revenue decline met with steady expenses, which compressed profitability relative to the prior quarter. Year-over-year growth in revenue and net profit remained solid. Finance costs continued their downward trajectory, and a reversal to a tax credit helped support the bottom line. The substantial drop in inter-segment revenue and the divergence between total net profit and earnings per share were the other defining features of the quarter.
Category: Manufacturing
The Generics segment is dedicated to delivering quality, cost-saving, and life-saving solutions to patients, partners, and healthcare systems globally. Biocon's Generics portfolio includes Active Pharmaceutical Ingredients (API) and Generic Formulations.
Category: Biopharmaceutical
Biocon's Biosimilars business operates primarily through its subsidiary, Biocon Biologics. This segment is focused on making potentially life-saving drugs affordable and accessible, thereby reducing health inequality and enabling patients to live prolonged, better quality lives.
Category: B2B Services
Biocon has a historical relationship with Syngene International Limited, a contract research and manufacturing company providing drug discovery and development services. Syngene operates globally, including in India, the United States, and Europe.
Category: Biopharmaceutical
The Novel Biologics segment is dedicated to enabling cutting-edge therapies, particularly in oncology and immunology. This portfolio comprises both in-house developed and partnered products.
Core Thesis: Biocon's business strategy is centered on delivering innovative biopharmaceutical medicines for unmet medical needs and providing branded formulations to the Indian market.
• Integrated Business Model: The company operates with a fully integrated business model, encompassing the entire drug value chain from pre-clinical discovery to clinical development and commercialization. • Affordable Innovation: Biocon focuses on transforming healthcare access through affordable innovation, making potentially life-saving drugs accessible and reducing health inequality. • Global Reach and Partnerships: Biocon engages in symbiotic partnerships to optimize manufacturing and commercialization costs, while accelerating scalability, and operates globally with subsidiaries and collaborations.